Max Rosett insider trades: Immunome (IMNM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Max reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | IMNM | ↓ Sell | 60,000 | $18.23 | $1.1M | Direct | Jun 17, 2026 (2d) |
| Apr 2, 2026 | IMNM | ↓ Sell | 65,000 | $21.92 | $1.4M | Direct | Apr 3, 2026 (1d) |
| Sep 19, 2024 | IMNM | ↓ Sell | 14,380 | $16.01 | $230K | Direct | Sep 20, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMNM insiders
Open-market trades in the last 12 months
About Max Rosett's insider trades
Max Rosett is Chief Financial Officer at Immunome (IMNM). Since Sep 19, 2024, Max has reported no open-market purchases and 3 sales worth $2.7M on SEC Form 4. In the last 12 months: 2 sales ($2.5M).
Their filings also include grants and awards (4 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.